News | Angiographic Catheter | July 25, 2016

Stryker Sustainability Solutions Recalls Angiodynamics Soft Vu Omni Flush Angiographic Catheters

Company has received reports of catheter tip separating from the main body, leading to a loss of device function and other complications

Stryker Sustainability Solutions, Angiodynamics Soft Vu Omni Flush Angiographic Catheters, recall

July 25, 2016 — Stryker Sustainability Solutions (formerly Ascent Healthcare Solutions) is recalling Angiodynamics Soft Vu Omni Flush Angiographic Catheters due to reports of separation of the tip of the catheter from the main body. Tip separation leads to loss of device function, possible surgical intervention to retrieve a separated segment, or other complications such as blocking blood flow to bodily organs.

Tip separation can also lead to internal organ injury and cause stroke, kidney failure and intestinal failure among other serious adverse health consequences, including death.

The recalled products include manufacturing dates Nov. 7, 2003 to Oct. 18, 2008, and distribution dates Jan. 5, 2004 to Dec. 3, 2008.

The Soft-Vu Omni Flush Angiographic Catheter is used to inject contrast dye into blood vessels in preparation for a cardiac angiogram, a type of X-ray used to diagnose heart conditions. The catheter is inserted into the body through a small puncture made in the skin and into a blood vessel.

On June 1, 2016, Stryker Sustainability Solutions sent a Customer Notification letter to customers informing them of the high possibility of tip separation during use. The letter also asked customers to:

  • Discontinue use of the affected lots of the recalled products;
  • Check their inventories for affected lots of the unused products;
  • Ship all affected products found back to Stryker; and
  • Acknowledge receipt of the letter by returning the enclosed Device Recall Effectiveness Check form by postal mail, or by contacting their Stryker Sustainability Sales Representative by email.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the U.S. Food and Drug Administration’s (FDA) MedWatch Safety Information and Adverse Event Reporting Program.

For more information: www.fda.gov/medwatch/report

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init